AC
TLSI icon

Anson Capital’s TriSalus Life Sciences TLSI Stock Holding History

Anson Capital’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,415
Closed -$135K – 70
2024
Q2 		$135K Hold
24,415
– – 0.13% 67
2024
Q1 		$238K Sell
24,415
-10,590
-30% -$97.7K 0.34% 55
2023
Q4 		$296K Hold
35,005
– – 0.49% 45
2023
Q3 		$179K Buy
+35,005
New +$287K 0.34% 56

Other funds holding TLSI

WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Anson Capital's TLSI Position: Q3 2024 in Review

Anson Capital sold out of TriSalus Life Sciences (TLSI) in Q3 2024, closing a stake of 24,415 shares — an estimated $135K sold.

Anson Capital first reported a position in TLSI in Q3 2023 and held it in 4 quarters. The position peaked at $296K in Q4 2023. 32 funds tracked by Wall St. Rank hold TLSI as of Q3 2024.

  • Anson Capital reported no remaining TriSalus Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Anson Capital sold 24,415 TriSalus Life Sciences shares in Q3 2024, an estimated $135K.
  • Anson Capital first reported a position in TriSalus Life Sciences in Q3 2023 and held it in 4 quarters.
  • Anson Capital's TriSalus Life Sciences position peaked at $296K in Q4 2023.
  • 32 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2024.

Based on Anson Capital's 13F filing for Q3 2024, filed 24 Oct 2024.